Skip to Main Content
Services Talent Knowledge
Site Search
Menu

Alert

Our attorneys stay on top of changes in legislation, agency regulations, case law, and industry trends—then craft timely legal alerts to keep clients up to date on legal developments important to their business.

August 20, 2020

Drug Manufacturers Seek Claims Data From 340b Contract Pharmacies

There’s been a surge of drug manufacturers demanding or requesting 340b claims data from covered entities’ contract pharmacies. It’s expected that the list of manufacturers is going to grow quickly. The manufacturers claim they need the data to mitigate duplicate 340b drug discounts and ineligible rebates. However, the manufacturers have not cited any reason to suspect covered entities or contract pharmacies are engaging in any activities that undermine program integrity—this appears to be an attempt to obtain data for other motives.     

It’s unclear what the consequences will be for covered entities that do not comply with the requests for their contract pharmacy claims data. However, Sanofi has advised covered entities that the failure to upload data every two weeks beginning on October 1 will result in Sanofi no longer allowing providers to place bill to or ship to replenishment orders for Sanofi products. Other manufacturers have also alluded to making it difficult for entities that do not comply to obtain medically necessary drugs to treat their patients.

The requests are excessive in scope, as safeguards already exist to avoid duplicate discounts under Medicaid and the 340b program. Indeed, the 340b program already has well-established guidelines for manufacturers to conduct audits of covered entities. The blanket requests from the manufacturers do not cite any authority for demanding data beyond these safeguards. Moreover, the demands place a huge administrative and cost burden on the covered entities and contract pharmacies.

We recommend that covered entities and their contract pharmacies work with legal counsel to customize a response that addresses their unique issues. Our Health Care Controversies Team can assist you in developing a response that best suits your entity’s needs.   

If you have any questions regarding the content of this alert, please contact Linda Clark, Health Care Controversies Team leader, at lclark@barclaydamon.com; Brad Gallagher, counsel, at bgallagher@barclaydamon.com; or another member of the firm’s Health Care Controversies Team.

Featured Media

Alerts

Third Circuit Ruling Recognizes Due Process Claim in Favor of Drug Distributors Subjected to Quasi-Governmental Credentialing Standards

Alerts

CPLR Article 52 Is Exclusive Vehicle to Challenge Use of Enforcement Procedures

Alerts

HHS OCR Issues Guidance on the Use of Remote Communication Technologies for Audio-Only Telehealth Services

Alerts

ADA Accessibility Lawsuits: Appellate Court Affirms Dismissal of Braille Gift Card Complaints

Alerts

Subchapter Five Debt Limit Update: What Was Down Is Heading Back Up!

Alerts

President Biden Uses Production Defense Act Authority to Suspend Tariffs on Solar Imports From China and Other Countries Amid Ongoing Commerce Probe

This site uses cookies to give you the best experience possible on our site and in some cases direct advertisements to you based upon your use of our site.

By clicking [I agree], you are agreeing to our use of cookies. For information on what cookies we use and how to manage our use of cookies, please visit our Privacy Statement.

I AgreeOpt-Out